Cover of: Tumor Therapy With Tumor Cells and Neuraminidase (Contributions to Oncology, Vol 27) | Hans H. Sedlacek Read Online
Share

Tumor Therapy With Tumor Cells and Neuraminidase (Contributions to Oncology, Vol 27)

  • 48 Want to read
  • ·
  • 65 Currently reading

Published by S. Karger AG (Switzerland) .
Written in English

Subjects:

  • Chemotherapy,
  • Oncology,
  • Cancer Chemotherapy,
  • Medical / Nursing

Book details:

The Physical Object
FormatHardcover
Number of Pages96
ID Numbers
Open LibraryOL12929848M
ISBN 103805545495
ISBN 109783805545495

Download Tumor Therapy With Tumor Cells and Neuraminidase (Contributions to Oncology, Vol 27)

PDF EPUB FB2 MOBI RTF

  TUMOR THERAPY OF NEOPLASTIC DISEASES WITH TUMOR CELLS AND NEURAMINIDASE: EXPERIMENTAL STUDIES ON CHESSBOARD VACCINATION IN TRANSPLANTATION TUMORS H. H. SEDLACEK, K. H. BENGELSDORFF, G. HAGMAYER and F. R. SELLER Research Laboratories of Behringwerke AG, Marburg, W. Germany (Received 16 Cited by: 4. In a tumor therapy model with spontaneous mammary tumors in mongrel dogs (1) using Vibrio cholerae neuraminidase (VCN)-treated autologous tumor cells success has been shown to depend on the number of cells injected. Tumor enhancement (1 × 10 8 cells), long-lasting tumor regression (2 × 10 7 cells) or only a transient therapeutic effect (2 Cited by: 2.   This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark. [All Breakthrough Coverage][1]![Figure][2] Domino effect. One such treatment, with the antibody in pink at the top, works by blocking a protein receptor, in purple, on a T cell. Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells.

Targeted therapy is a treatment that targets the tumor’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of tumor cells while limiting damage to healthy cells. Not all tumors have the same targets. Then the T cells are returned to the patient’s body. Targeted therapy and combined treatments. As noted in Types of Treatment, research continues on targeted therapy. Monoclonal antibodies are a type of targeted therapy that blocks tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor. Tumor-associated antigens: proteins often expressed at abnormally high levels on tumor cells and can be used to target them; also found on normal cells at lower levels Adoptive cell therapy takes a patient’s own immune cells, expands or otherwise modifies them, and then reintroduces them to the patient, where they can seek out and eliminate. Searching the medical database PubMed for "Mebendazole cancer", one finds papers such as Potential anti-cancer drugs commonly used for other indications, Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors, Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo.

  Understanding Your Pathology Report: Lung Cancer. When your lung was biopsied, the samples taken were studied under the microscope by a specialized doctor with many years of training called a pathologist sends your doctor a report that gives a diagnosis for each sample taken. Information in this report will be used to help manage your care. Purchase Mesenchymal Stem Cells in Cancer Therapy - 1st Edition. Print Book & E-Book. ISBN ,   1. Introduction. Low targeting efficiency limits the applications of nanoparticles in cancer therapy1., 2., Mesenchymal stem cells (MSC) have great potential for treating tissue injury and degenerative disease and for use in immune disorder therapy onally, anti-tumorigenic effects and low immunogenicity make MSC a kind of ideal vehicle for anti-tumor drug delivery5., 6. Basic scientists at the Brain Tumor Center are developing monoclonal antibodies that can attach to specific proteins on the surface of tumor cells. The immune system then recognizes these antibodies and eliminates the cancerous cells they are attached to. Although this new approach to therapy is still under investigation, researchers anticipate.